I'm usually pretty neutral/slightly bullish on RAP but this is poor, SleepCheck ~1.1k downloads this quarter. so revenue from Sleepcheck based on previous 4C and lag time $15k + ~75% of 1.1k downloads this quarter 750 download @ $6.80, so 18-20k from SleepCheck and AstraZeneca provided the other $22k.....
Can't be understated how poor the SleepCheck market uptake is right now. I was hopeful but if Android doesn't boost these numbers it's likely a complete product bust with costings including development, staff, etc.. let alone the $450k marketing spent seen as in the latest 4C.
This should be a key questioning point for TK and co today.
Other Notes:
- The main game looks to be finally showing outcomes in ResAppD with Illara finishing and Medgate starting
- No hardware 4C device mentioned anywhere
- No Mayfield clinic mention
Opportunity cost is hitting home hard on this stock in a market like we are seeing.
Ann: Quarterly Activities Report and Appendix 4C, page-11
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #